

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Zelboraf (vemurafenib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zelboraf (vemurafenib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zelboraf (vemurafenib) may be approved if the following criteria are met:

Individual has a diagnosis of one of the following:

- I. Unresectable or metastatic melanoma with BRAF V600E mutation; **AND**
- II. BRAF test results must be confirmed;

OR

- III. Colon Cancer (NCCN 2A);

OR

- IV. Rectal Cancer (NCCN 2A);

OR

- V. Non-Small Cell Lung Cancer with BRAF V600E mutation (NCCN 2A); **AND**
- VI. BRAF test results must be confirmed;

OR

- VII. Erdheim-Chester Disease with BRAF V600 mutation; **AND**
- VIII. BRAF test results must be confirmed;

OR

- IX. Hairy cell leukemia (NCCN 2A);

OR

PAGE 1 of 2 03/28/2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

CRX-ALL-0359-19

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

X. Thyroid Carcinoma, Follicular, Papillary, or Hurthle Cell (NCCN 2A);

OR

XI. Central Nervous System (CNS) cancer; **AND**

XII. Individual is using for recurrent disease for brain metastases if active against primary tumor (melanoma) (NCCN 2A).

Zelboraf (vemurafenib) may **not** be used for the following:

- I. Individual is using for the treatment of wild-type BRAF melanoma.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.